Watch Revolution Medicines Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Revolution Medicines Inc (RVMD) stock: price, quality, comparison
Price, quality, revenue and earnings and the peer comparison for Revolution Medicines Inc, from audited financials.
Price: $192.28. No valuation: the company's figures do not support a reliable fair value right now, so we deliberately show none.
Revenue growth (quarter YoY) −95.2% (industry 0.0%)
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
RM
Thin data
Nov 8, 2026
Thin data
Nov 8, 2026
Revolution Medicines Inc
RVMD · USInsiders sold $102.9M (6M)
Quality 26/100
Weak Growth (revenue 5y −10.5 %/yr in USD)
Negative free cash flow
Trails peers (1/6)
Narrow moat 10/100 · thin data
Downbeat coverage
Thin data
No fair value
Watch Revolution Medicines Inc for free: we tell you when fair value or trend changes.
Watch for free
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Company profile
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
Show moreShow less
The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Quality Score breakdown
Overall quality
26/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability
0
How much profit the company makes from its sales and capital
Quality Growth
25
Are margins and returns getting better?
Cashflow
20
Do the profits arrive as real cash?
Financial strength
89
Debt, balance sheet and risk of trouble
Investment
0
Does it invest with discipline instead of growing at any price?
Low Volatility
14
How calm the share price moves, does not count
Price momentum
74
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high
91
Distance to the 52-week high, does not count
New shares
0
Buys back shares or issues new ones?
Insider trades
In the last 6 months, 10 officers or directors sold shares worth $102.9M and none bought.
- SaleAnthony ManciniOfficer9× since Mar 25, 2026: 73,310 shares, avg. $139.45$10.2MOct 26, 2026
- SaleAlan B. SandlerChief Development Officer2× since Sep 16, 2026: 6,650 shares, avg. $201.99$1.3MSep 29, 202610b5-1 plan
- SaleJeff CisliniSVP & General Counsel8× since Nov 18, 2025: 83,124 shares, avg. $175.79$14.6MSep 25, 202610b5-1 plan
- SaleElizabeth M AndersonDirector10,143 shares at $193.04$2.0MSep 22, 202610b5-1 plan
- SaleMark A GoldsmithOfficer, Director10× since Nov 12, 2025: 400,273 shares, avg. $135.22$54.1MSep 16, 202610b5-1 plan
- SaleMargaret A HornChief Operating Officer6× since Dec 16, 2025: 189,397 shares, avg. $133.34$25.3MSep 16, 202610b5-1 plan
- SaleStephen Michael KelseyOfficer5× since Dec 16, 2025: 112,024 shares, avg. $190.43$21.3MSep 16, 202610b5-1 plan
- SaleJack AndersChief Financial Officer8× since Nov 11, 2025: 58,050 shares, avg. $122.88$7.1MSep 16, 202610b5-1 plan
- SaleLorence H. KimDirector2× since Aug 31, 2026: 73,090 shares, avg. $204.78$15.0MSep 8, 202610b5-1 plan
- SaleSushil PatelDirector5,580 shares at $187.99$1.0MJun 29, 202610b5-1 plan
Plus 2 more entries from the last 12 months.
Plus 20 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−67.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−35.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.5%
’18
’19
’20
’21
’22
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−200.0% (2018) → −4,207.1% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Watch RVMD, get fair value alerts →
Recent news
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.
Very negative
Recent news coverage is unusually downbeat.
- Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"
- Revolution Medicines to Participate in November 2026 Investor Conferences
- Revolution Medicines (RVMD) Stock Looks Above Fair Value Today
- Revolution Medicines (RVMD) Following New Pancreatic Cancer Data Looks Undervalued
Compare Revolution Medicines Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Incyte Corporation INCY | $119.65 | $199.23 | +67% | vs RVMD |
| Regeneron Pharmaceuticals, Inc REGN | $904.35 | $1,275 | +41% | vs RVMD |
| Genmab A/S GMAB | kr 3,527 | kr 3,999 | +13% | vs RVMD |
| WuXi Biologics (Cayman) Inc 2269 | HK$47.62 | HK$53.55 | +12% | vs RVMD |
| Samsung Biologics Co 207940 | 1,516,000 KRW | 1,667,600 KRW | +10% | vs RVMD |
| Vertex Pharmaceuticals Incorporated VRTX | $547.09 | $596.75 | +9% | vs RVMD |
| argenx SE ARGX | $927.21 | $908.40 | −2% | vs RVMD |
| CSL Limited CSL | A$202.04 | A$183.04 | −9% | vs RVMD |
| Celltrion, Inc 068270 | 211,000 KRW | 74,945 KRW | −64% | vs RVMD |
| Royalty Pharma plc RPRX | $67.30 | $19.01 | −72% | vs RVMD |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Evidence & backtest34 years, failed companies included
Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
Frequently asked questions
What is the quality score of RVMD?
Revolution Medicines Inc has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Revolution Medicines Inc (RVMD)?
Revolution Medicines Inc reported trailing-twelve-month revenue of about $742K (latest available figure, as of Nov 8, 2026).
How solid is the balance sheet of Revolution Medicines Inc (RVMD)?
Balance-sheet figures for Revolution Medicines Inc (as of Nov 8, 2026): return on equity −79.1%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
Which stocks are comparable to Revolution Medicines Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Revolution Medicines Inc (RVMD)?
The closing price on Nov 6, 2026 was $192.28. We carry closing prices from our data provider, not a live tick.
Key figures of Revolution Medicines Inc
How large is the market capitalisation of Revolution Medicines Inc (RVMD)?
The market capitalisation of Revolution Medicines Inc is $40.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Revolution Medicines Inc (RVMD)?
Earnings per share at Revolution Medicines Inc are $−9.88. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Revolution Medicines Inc (RVMD)?
The return on equity (ROE) of Revolution Medicines Inc is −79.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Revolution Medicines Inc (RVMD)?
On an EBIT basis the return on assets of Revolution Medicines Inc is −31.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Revolution Medicines Inc (RVMD)?
Revenue at Revolution Medicines Inc is growing −95.2% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Revolution Medicines Inc (RVMD) generate?
The free cash flow of Revolution Medicines Inc is −$914M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Revolution Medicines Inc (RVMD) hold?
Revolution Medicines Inc holds more cash than debt, $225M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Revolution Medicines Inc in the live analysis
One click puts Revolution Medicines Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.